Bienaime Jean Jacques
BIENAIME JEAN JACQUES, DIR, reported a transaction classified as grant at Keros Therapeutics, Inc. involving 7433.000000 shares for an estimated $0.00. Reported holdings after the transaction were 7433.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Jun 03, 2026
- Filing date
- Jun 05, 2026
How reported position traded is calculated
Not calculated for derivative securities.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
KROS price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001221590-26-000013 Stock Option (right to buy)
- Transaction date
- Jun 03, 2026 Filed Jun 05, 2026, 08:15 PM · 2d delay
- Shares
- 7,433 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 7,433 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-6 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - timely_filing+4 points
reporting_delay_days = 2
Filing reported within two business days of the transaction. - derivative_transaction-16 points
is_derivative = true
Derivative exercise rows are less discretionary than open-market purchases.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
No officer title
- F1
Represents a restricted stock unit ("RSU") award. The RSUs fully vest on the earlier of (A) June 3, 2027 and (B) the date of the Issuer's 2027 annual meeting of stockholders, subject to the Reporting…
- F2
The option shall vest in equal quarterly installments over the 12 months following June 3, 2026, provided that the grant will in any case be fully vested on the date of Issuer's 2027 annual meeting of…
0 other transactions
0 recent txs